drugset / Trial / NCT06343532
SXC-2023 Cocaine Interaction Study
Phase 1
Completed
19 enrolled
National Institute on Drug Abuse (NIDA)
Altasciences Company Inc. · collabPromentis Pharmaceuticals, Inc. · collabTechnical Resources International, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to determine whether there are any interactions between the study drug and cocaine. Researchers will compare a treatment group and a placebo group to see if they experience any effects when administered cocaine after taking the treatment/placebo.
Timeline
- Start
- 2024-10-08
- Primary completion
- 2024-12-30
- Completion
- 2024-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SXC-2023 | Unknown | 800 mg | — |